

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

PFIZER

2. Address:

325 7TH STREET, NW, #1200, WASHINGTON, DC 20004

3. Principal place of business (if different from line 2):

4. Contact Name: BARBARA BONFIGLIO

Telephone: 2027837070

E-mail (optional): BARBARA.BONFIGLIO@PFIZER.COM

Senate ID #: 31326-12

House ID #:

7. Client Name: Self

TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30): **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report: => Termination Date: _____ 11. No Lobbying Activity:

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more: => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more: => Expenses (nearest \$20,000): 5,800,000.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only
 Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
 Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: PFIZER Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: AGR (one per page)

16. Specific lobbying issues:

HR 2206, Veterinary Workforce Expansion Act of 2005, increased funding for veterinary schools HR 2744, Agriculture Appropriations, pharmaceutical counterfeiting, importation S 914, Veterinary Workforce Expansion Act of 2005, increased funding for veterinary schools

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: JUDGE, DOLLY

Covered Official Position (if applicable): N/A

Name: LAMARCA, LOUIS A.

Covered Official Position (if applicable): N/A

Name: PRINCIPI, ANTHONY J

Covered Official Position (if applicable): N/A

Name: WILSON, ANNE

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: PFIZER Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: ANI (one per page)

16. Specific lobbying issues:

S 1926, Animal Enterprise Terrorism Act, research safety HR 4239, Animal Enterprise Terrorism Act, research safety animal health (no bills)

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ROBERTS, RON

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: PFIZER Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

H Con Res 95, Budget Reconciliation, pharmaceutical counterfeiting, importation HR 2744, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2006, pharmaceutical counterfeiting, importation HR 2862, Science, State, Justice, Commerce, and Related Agencies Appropriations Act, 2006, pharmaceutical counterfeiting, importation HR 3010, Departments of Labor, Health and Human Services, and Education, and related Agencies Appropriations Act, 2006, pharmaceutical counterfeiting, importation S Con Res 18, Budget reconciliation, pharmaceutical counterfeiting, importation S Con Res 83, Budget resolution, non-interference HR 6134, Ryan White Care Act, appropriations S 2339, Ryan White Care Act, appropriations

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: JUDGE, DOLLY

Covered Official Position (if applicable): N/A

Name: LAMARCA, LOUIS A.

Covered Official Position (if applicable): N/A

Name: PRINCIPI, ANTHONY J

Covered Official Position (if applicable): N/A

Name: ROBERTS, RON

Covered Official Position (if applicable): N/A

Name: TERRY, MYRON

Covered Official Position (if applicable): N/A

Name: WILSON, ANNE

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

House of Representatives Senate

Registrant Name: PFIZER Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

HR 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation HR 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues S 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation S 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues S 2300, Lower PRICED Drugs Act, legislation on pediatric exclusivity, citizens petitions HR 6022, Lower PRICED Drugs Act, legislation on pediatric exclusivity, citizens petitions S 3695, To Amend the Federal Food, Drug & Cosmetic Act to prohibit the marketing of authorized generic drugs, authorized generics HR 5993, To Amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs HR 5120, To amend title 35, United States Code, to conform certain filing provisions within the Patent and Trademark Office. HR 5418, To establish a pilot program in certain United States district courts to encourage enhancement of expertise in patent cases among district judges S 3818, Patent Reform Act of 2006 S 3175, Life-Saving Medicines Export Act of 2006, compulsory licensing S 3834, Online Pharmacy Consumer Protection Act of 2006, prescription drugs S 1903, Generic Prescription Drug Fairness Act of 2005, authorized generics and rebates

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: JUDGE, DOLLY

Covered Official Position (if applicable): N/A

Name: LAMARCA, LOUIS A.

Covered Official Position (if applicable): N/A

Name: PRINCIPI, ANTHONY J

Covered Official Position (if applicable): N/A

Name: TERRY, MYRON

Covered Official Position (if applicable): N/A

Name: WILSON, ANNE

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

House of Representatives Senate

Registrant Name: PFIZER Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CSP (one per page)

16. Specific lobbying issues:

HR 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues HR 870, The PhRMA Research and Manufacturers Accountability (PhRMA) Act, drug safety S 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation S 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues S 470, The Fair Access to Clinical Trials ("FACT") Act of 2005, drug safety S 930, Food and Drug Administration Safety Act of 2005, drug safety HR 5156, Counterfeit Drug Prevention Act, pharmaceutical counterfeiting S 3834, Online Pharmacy Consumer Protection Act of 2006, drug safety HR 2300, Lower PRICED Drugs Act, legislation on pediatric exclusivity, citizens petitions HR 4157, Better Health Information System Act, health information technology HR 5975, Prescription Drug Effectiveness Act, drug prescriptions S 2699, Neglected Diseases Elimination Act, promote R&D HR 2090, The Food and Drug Administration Improvement Act of 2005, drug safety HR 3196, The Fair Access to Clinical Trials ("FACT") Act of 2005, drug safety HR 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation, drug safety

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: JUDGE, DOLLY

Covered Official Position (if applicable): N/A

Name: LAMARCA, LOUIS A.

Covered Official Position (if applicable): N/A

Name: PRINCIPI, ANTHONY J

Covered Official Position (if applicable): N/A

Name: WILSON, ANNE

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: PFIZER Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: ENV (one per page)

16. Specific lobbying issues:

HR 1215 Green Chemistry Research and Development Act of 2005, environmental conservation S 1270, Green Chemistry Research and Development Act of 2005, environmental conservation

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: PRINCIPI, ANTHONY J

Covered Official Position (if applicable): N/A

Name: TERRY, MYRON

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: PFIZER Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

S 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation S 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues HR 3010, Department of Labor, Health and Human Service, and Education, and Related Agencies Appropriations Act, 2006, access to prescription drugs HR 3971, Social Services Emergency Relief and Recovery Act of 2005, access to prescription drugs HR 5993, Authorized Generics Prohibition, authorized generics S 3695, Authorized Generics Prohibition, authorized generics HR 4157, Better Health Information System Act, health information technology S 2300, Lower PRICED Drug Act, generic drug access, legislation on pediatric exclusivity, citizens petitions HR 6134, Ryan White Care Act, reauthorization S 2339, Ryan White Care Act, reauthorization HR 5975, Prescription Drug Comparative Effectiveness Act, drug prescriptions S 1355, Better Healthcare Through Information Technology Act, health information technology HR 6289, Personalized Health Information Act of 2006, health information technology HR 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation HR 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues

17. House(s) of Congress and Federal agencies contacted:

Executive Office of the President (EOP)
Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CAREY, CHRISTOPHER
Covered Official Position (if applicable): N/A
Name: JUDGE, DOLLY
Covered Official Position (if applicable): N/A
Name: LAMARCA, LOUIS A.
Covered Official Position (if applicable): N/A
Name: ROBERTS, RON
Covered Official Position (if applicable): N/A
Name: TERRY, MYRON
Covered Official Position (if applicable): N/A
Name: WILSON, ANNE
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: PFIZER Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

HR 3010, Labor, HHS Appropriations, prescription drug benefit, price controls HR 712, Medicare Prescription Drug Sensibility Act, prescription drug benefit S 1932, Deficit Reduction Omnibus Reconciliation Act, prescription drug payment issues S 438, Medicare Access to Rehabilitation Services Act of 2005 Medicare prescription drug benefit implementation (no bills) Medicaid rebates (no bills) Medicaid coverage (no bills)

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CAREY, CHRISTOPHER

Covered Official Position (if applicable): N/A

Name: JUDGE, DOLLY

Covered Official Position (if applicable): N/A

Name: LAMARCA, LOUIS A.

Covered Official Position (if applicable): N/A

Name: PRINCIPI, ANTHONY J

Covered Official Position (if applicable): N/A

Name: TERRY, MYRON

Covered Official Position (if applicable): N/A

Name: WILSON, ANNE

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: PFIZER Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: SCI (one per page)

16. Specific lobbying issues:

HR 2122, The Project BioShield Act of 2003, pharmaceutical research and development, security S 3807, Enhancing Drug Safety and Innovation Act of 2006, drug safety, DTC

17. House(s) of Congress and Federal agencies contacted:

Commerce, Dept of (DOC)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: JUDGE, DOLLY
Covered Official Position (if applicable): N/A
Name: LAMARCA, LOUIS A.
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: PFIZER Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TOR (one per page)

16. Specific lobbying issues:

S 5, The Class Action Fairness Act of 2005, class action reform S 852, The Fairness in Asbestos Injury Resolution Act of 2005, asbestos litigation S 3734, Multidistrict Litigation Restoration Act, multidistrict legislation

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: DAVIS, KIMBERLY

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: PFIZER Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRD (one per page)

16. Specific lobbying issues:

HR 2862, Science, State, Justice Appropriations, market access HR 3045, Dominican Republic-Central America-United States Free Trade Agreement Implementation Act, Intellectual property, foreign price controls, market access restrictions HR 3283, Agreement The United States Trade Rights Enforcement Act of 2005, intellectual property, market access, foreign price controls S 307, Agreement The United States Trade Rights Enforcement Act of 2005, intellectual property, market access, foreign price controls HR 6111, Tax Relief and Health Care Act of 2006, trade provisions Intellectual property protection (no bills) International pharmaceutical market access (no bills) WTO accession and implementation issues (no bills) US-Korea Free Trade Agreement (no bills) US-Peru Free Trade Agreement (no bills) US-Columbia Free Trade Agreement (no bills)

17. House(s) of Congress and Federal agencies contacted:

Commerce, Dept of (DOC)
Executive Office of the President (EOP)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
Patent & Trademark Office (PTO)
SENATE
State, Dept of (DOS)
U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area:

Name: DAMOND, JOSEPH
Covered Official Position (if applicable): N/A
Name: HENNING, STEPHANIE
Covered Official Position (if applicable): WAYS AND MEANS COMMITTEE STAFF

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Apr 27, 2007

Printed Name and Title: ANTHONY J. PRINCIPI -

Registrant Name: PFIZER Client Name: Self

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

Name: BAGGER, RICH

Name: BENNETT, CATHERINE P.

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Apr 27, 2007

Printed Name and Title: -